Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lirafugratinib hydrochloride by Relay Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lirafugratinib hydrochloride is under clinical development by Relay Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor...